← All trials
NCT05397834
Phase 1Interventional
Includes initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients.
View on ClinicalTrials.gov ↗Timeline
- Start date
- May 11, 2022
- Primary completion
- Jun 21, 2022
- Completion date
- Sep 1, 2022
- First posted
- May 31, 2022
- Last posted
- May 31, 2022
- Enrollment
- 36
- Arms / groups
- 2 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Respirent Pharmaceuticals Co Ltd.Lead sponsor
- BECRO Ltd.Collaborator
- BECRO Ltd.Overall official - principal investigator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.